Phio Pharmaceuticals Corp. - Common Stock (PHIO)
Frequently Asked Questions About Phio Pharmaceuticals Corp. - Common Stock (PHIO)
How can interested parties contact Phio Pharmaceuticals?
Interested parties can contact Phio Pharmaceuticals through their official website, where contact information is provided for inquiries regarding investor relations, partnerships, or general information. They typically have dedicated email addresses or phone numbers to facilitate communication with stakeholders.
How does Phio communicate with its investors?
Phio Pharmaceuticals maintains transparent communication with its investors through regular updates, including quarterly earnings reports, press releases, and corporate presentations. They also participate in investor conferences and provide information via their official website to keep stakeholders informed about company developments and progress.
How does Phio ensure the safety of its therapies?
Phio Pharmaceuticals adheres to strict regulatory guidelines and conducts thorough preclinical and clinical studies to assess the safety and efficacy of its therapies. The data collected from these studies is submitted to regulatory authorities to ensure that their products meet safety standards before being brought to market.
How does Phio Pharmaceuticals differentiate itself from competitors?
Phio Pharmaceuticals differentiates itself through its proprietary self-delivering RNA technology, which offers a unique approach to cancer treatment. This technology simplifies RNA delivery, enhances therapeutic efficacy, and potentially reduces side effects compared to traditional methods, providing Phio with a competitive edge in the biopharmaceutical landscape.
Is Phio Pharmaceuticals publicly traded?
Yes, Phio Pharmaceuticals Corp. is publicly traded on the Nasdaq under the ticker symbol 'PHIO'. Being a publicly traded company allows Phio to raise capital from investors to fund its clinical development efforts and operational activities.
What are Phio's lead product candidates?
Phio Pharmaceuticals has several lead product candidates, including PH-762, which is designed for the treatment of solid tumors. PH-762 is currently being investigated in clinical trials to evaluate its safety and efficacy in enhancing anti-tumor immune responses in patients.
What are the future plans for Phio Pharmaceuticals?
Phio Pharmaceuticals plans to continue advancing its pipeline of RNA-based therapies through ongoing clinical trials and to seek partnerships that may facilitate commercialization efforts. Their focus will remain on maximizing therapeutic potential and addressing unmet medical needs in cancer treatment.
What challenges does Phio Pharmaceuticals face?
Like many biotechnology companies, Phio Pharmaceuticals faces challenges such as securing funding for research and development, navigating regulatory pathways, and demonstrating the safety and efficacy of their therapies through clinical trials. Additionally, competition within the biotech space can impact their market position and growth prospects.
What does Phio Pharmaceuticals Corp. do?
Phio Pharmaceuticals Corp. is a biotechnology company focused on developing innovative cancer immunotherapy treatments. They utilize their proprietary therapeutic platform, which leverages self-delivering RNA-based therapeutics, to design treatments that aim to enhance the immune system's ability to identify and destroy cancer cells.
What is Phio Pharmaceuticals' vision for the future?
Phio Pharmaceuticals envisions a future where their innovative RNA-based therapies can significantly improve treatment outcomes for cancer patients. Their goal is to advance their product candidates through clinical trials and to ultimately achieve regulatory approval, making their therapies available to those in need.
What is Phio's business model?
Phio Pharmaceuticals operates under a business model primarily focused on research and development of its proprietary therapies. They aim to advance their product candidates through clinical trials and regulatory processes, ultimately seeking partnerships or collaborations with larger pharmaceutical companies for commercialization and market distribution.
What is the importance of RNA-based therapies in oncology?
RNA-based therapies play a crucial role in oncology as they offer a novel mechanism for targeting cancer cells and modulating the immune response. These therapies have the potential to overcome limitations of traditional treatments, such as non-specificity and side effects, by precisely directing the immune system to recognize and attack cancer cells.
What is the potential market for Phio's therapies?
The potential market for Phio Pharmaceuticals' therapies is substantial, given the increasing prevalence of cancer and the growing demand for effective treatments. The global oncology therapeutics market is expected to expand, creating opportunities for Phio to capture significant market share with its innovative RNA-based therapies.
What is the significance of Phio's self-delivering RNA technology?
Phio's self-delivering RNA technology is significant because it allows for direct delivery of therapeutic RNA molecules into cells without the need for additional transfection agents. This technology improves the overall efficiency and effectiveness of delivering RNA therapies, making it a promising approach in the treatment of various cancers.
What is the status of Phio's clinical trials?
Phio Pharmaceuticals is actively conducting clinical trials for their lead product candidates. As of now, they are focused on evaluating the safety and efficacy of PH-762 in patients with solid tumors. The ongoing trials aim to gather critical data that will support the advancement of their product candidates in the regulatory approval process.
What partnerships does Phio Pharmaceuticals have?
Phio Pharmaceuticals has sought strategic partnerships to enhance its research and development capabilities. Collaborations with academic institutions, research organizations, and pharmaceutical companies can provide valuable resources, expertise, and funding to support its clinical development programs.
Where is Phio Pharmaceuticals headquartered?
Phio Pharmaceuticals Corp. is headquartered in Marlborough, Massachusetts. This location provides the company with access to a robust biotechnology ecosystem and a skilled workforce, facilitating collaboration and research in the field of therapeutic development.
Who are the key members of Phio's management team?
Phio Pharmaceuticals is led by a skilled management team with extensive experience in the biotechnology and pharmaceutical industries. Key figures typically include executives with backgrounds in drug development, operations, finance, and regulatory affairs, which collectively support the company's strategic objectives.
What is the current price of Phio Pharmaceuticals Corp. - Common Stock?
The current price of Phio Pharmaceuticals Corp. - Common Stock is 1.210
When was Phio Pharmaceuticals Corp. - Common Stock last traded?
The last trade of Phio Pharmaceuticals Corp. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Phio Pharmaceuticals Corp. - Common Stock?
The market capitalization of Phio Pharmaceuticals Corp. - Common Stock is 5.78M
How many shares of Phio Pharmaceuticals Corp. - Common Stock are outstanding?
Phio Pharmaceuticals Corp. - Common Stock has 4.78M shares outstanding.